Clinical trial
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG…
NCT00419341 · CSL Behring, Industry · Completed
Key facts
| NCT number | NCT00419341 |
|---|---|
| Title | Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy |
| Official title | A Phase III Open-Label, Prospective, Multicenter Study of the Efficacy, Tolerability, Safety, and Pharmacokinetics of Immune Globulin Subcutaneous (Human), IgPro20 in Subjects With Primary Immunodeficiency (PID) |
| Lead sponsor | CSL Behring, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Primary Immune Deficiency |
| Intervention type | Biological |
| Interventions | Human Normal Immunoglobulin for Subcutaneous Administration |
| Enrollment | 49 |
| Start date | Nov 1, 2006 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 8, 2007 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: